Discussing the famous article in The LANCET Vol 49 August 2024
Overall cardiovascular mortality is expected to increase by 91.2% between 2025 and 2050, despite a 23.0% decline in the age-standardized cardiovascular mortality rate (ASMR). Coronary heart disease (115 deaths per 100,000 population) and stroke (63 deaths per 100,000 population) will remain the main drivers of ASMR in 2050. Central Asia will have the highest ASMR (676 deaths per 100,000 population), more than three times the rate for all of Asia (186 deaths per 100,000 population), while the high-income subregions of Asia will have an ASMR of 22 deaths per 100,000 in 2050. High systolic blood pressure will contribute to the highest ASMR in all of Asia (105 deaths per 100,000 population), except for Central Asia, where high fasting plasma glucose will predominate (546 deaths per 100,000 population).
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
In the second part of the interview, we will talk about nonstatin methods of lipid management.
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in Asian countries, with low-density lipoprotein cholesterol (LDL) being the causal risk factor. Although statins have a long history of efficacy and safety, nonstatin methods can be used to reduce LDL cholesterol as an adjunct or alternative to statin therapy. This interview discusses the indications, evidence, and important recommendations for prescribing non-statin lipid-lowering therapy and offers a practical approach to determining when to start non-statin therapy.
• Omega 3 fatty acids reduce TG but not LDL, doubts about improving overall CV prognosis, are the data of Omega 3 FAs in treatment at risk studies convincing? Omega 3 FAs and the risk of AF, which patients are not indicated for Omega 3 FAs
• REDUCE-IT study STRENGTH study, JELIS study
• Eicosapentaenoic acid (EPA) and the risk of bleeding. EPA + DHA dosage forms
Interview conducted by prof. Yezhov M.V. The use of statins to reduce LDL cholesterol remains a key factor in the prevention and treatment of ASCVD; target LDL cholesterol levels should be individualized based on cardiovascular risk profiles and shared decision making. Non-statin lipid-lowering therapies have been shown to reduce the risk of cardiovascular disease when taken in combination with or instead of statins.
